Osteoporosis Drugs Market Report by Product Type (Bisphosphonates, Calcitonin, Rank Ligand Inhibitor, Parathyroid Hormone Therapy (PTH), Selective Estrogen Receptor Modulators (SERMs), Sclerostin Inhibitor, and Others), Route of Administration (Oral, Injectable, and Others), and Region 2026-2034

Osteoporosis Drugs Market Report by Product Type (Bisphosphonates, Calcitonin, Rank Ligand Inhibitor, Parathyroid Hormone Therapy (PTH), Selective Estrogen Receptor Modulators (SERMs), Sclerostin Inhibitor, and Others), Route of Administration (Oral, Injectable, and Others), and Region 2026-2034

Report Format: PDF+Excel | Report ID: SR112026A3104

Market Overview:

The global osteoporosis drugs market size reached USD 18.0 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 25.4 Billion by 2034, exhibiting a growth rate (CAGR) of 3.82% during 2026-2034.

Report Attribute 
Key Statistics
Base Year
2025
Forecast Years
2026-2034
Historical Years
2020-2025
Market Size in 2025
USD 18.0 Billion
Market Forecast in 2034
USD 25.4 Billion
Market Growth Rate 2026-2034 3.82%

Osteoporosis is a disease that causes deterioration of bone tissues and strength. It is diagnosed by performing different scans, such as X-ray, computed tomography (CT) and magnetic resonance imaging (MRI). Various drugs are currently available in different formulations, ranging from regular tablets to intravenous (IV) infusions, for alleviating the symptoms of osteoporosis. These drugs help restore the balance of resorption and formation, repair microscopic defects in bones, reduce the risk of fractures and improve the overall muscle strength of the patients.

Osteoporosis Drugs Market Size

To get more information on this market Request Sample

The growing prevalence of osteoporosis on account of sedentary lifestyles, excessive consumption of alcohol, and rising utilization of tobacco represent the key factors bolstering the growth of the market. The increasing number of individuals who have celiac disease, kidney or liver disease, cancer, lupus, multiple myeloma and rheumatoid arthritis is further accelerating the market growth. Moreover, bone mass loss increases with age, which raises the risk of developing osteoporosis among older people. Consequently, the rising geriatric population is positively influencing the demand for osteoporosis drugs worldwide. Furthermore, several governing authorities are developing novel therapeutics, which is contributing to the market growth. For instance, the US Food and Drug Administration (FDA) has approved novel osteoporosis drugs for postmenopausal women who are at a high risk of fractures or are intolerant to other osteoporosis therapies. Besides this, a wide range of drugs in late-stage clinical trials is anticipated to propel the market growth in the coming years.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global osteoporosis drugs market report, along with forecasts at the global, regional and country level from 2026-2034. Our report has categorized the market based on product type and route of administration.

Breakup by Product Type:

  • Bisphosphonates
  • Calcitonin
  • Rank Ligand Inhibitor
  • Parathyroid Hormone Therapy (PTH)
  • Selective Estrogen Receptor Modulators (SERMs)
  • Sclerostin Inhibitor
  • Others
     

Breakup by Route of Administration:

Osteoporosis Drugs Market By Route of Administration

Access the comprehensive market breakdown Request Sample

  • Oral
  • Injectable
  • Others
     

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa
     

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Amgen Inc., Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Merck & Co. Inc., Novartis AG, Pfizer Inc., Radius Health Inc., Teva Pharmaceutical Industries Ltd. and UCB S.A.

Report Coverage:

Report Features Details
Base Year of the Analysis 2025
Historical Period 2020-2025
Forecast Period 2026-2034
Units Billion USD
Segment Coverage Product Type, Route of Administration, Region
Region Covered Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered Amgen Inc., Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Merck & Co. Inc., Novartis AG, Pfizer Inc., Radius Health Inc., Teva Pharmaceutical Industries Ltd. and UCB S.A.
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

Frequently Asked Questions About the Osteoporosis Drugs Market Report

The global osteoporosis drugs market was valued at USD 18.0 Billion in 2025.

We expect the global osteoporosis drugs market to exhibit a CAGR of 3.82% during 2026-2034.

The rising prevalence of osteoporosis, along with the increasing demand for osteoporosis drugs as they help to restore the balance of resorption and formation, repair microscopic defects in bones, reduce the risk of fractures, etc., is primarily driving the global osteoporosis drugs market.

The sudden outbreak of the COVID-19 pandemic had led to the growing number of R&D activities pertaining to specialty generic drugs for combating the spread of the coronavirus infection, thereby negatively impacting the global market for osteoporosis drugs.

Based on the product type, the global osteoporosis drugs market has been segmented into bisphosphonates, calcitonin, rank ligand inhibitor, Parathyroid Hormone Therapy (PTH), Selective Estrogen Receptor Modulators (SERMs), sclerostin inhibitor, and others. Among these, bisphosphonates currently hold the majority of the total market share.

Based on the route of administration, the global osteoporosis drugs market can be divided into oral, injectable, and others. Currently, oral exhibits a clear dominance in the market.

On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.

Some of the major players in the global osteoporosis drugs market include Amgen Inc., Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Merck & Co. Inc., Novartis AG, Pfizer Inc., Radius Health Inc., Teva Pharmaceutical Industries Ltd., and UCB S.A.

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Osteoporosis Drugs Market Report by Product Type (Bisphosphonates, Calcitonin, Rank Ligand Inhibitor, Parathyroid Hormone Therapy (PTH), Selective Estrogen Receptor Modulators (SERMs), Sclerostin Inhibitor, and Others), Route of Administration (Oral, Injectable, and Others), and Region 2026-2034
Purchase Options Discount
Offer
Benefits of Customization
  • Personalize this research
  • Triangulate with your data
  • Get data as per your format and definition
  • Gain a deeper dive into a specific application, geography, customer, or competitor
  • Any level of personalization

Get in Touch With Us

UNITED STATES

Phone: +1-201-971-6302

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials